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P-glycoprotein (P-gp), a transmembrane permeability glycoprotein, is a member of ATP binding cassette 
(ABC) super family that functions specifically as a carrier mediated primary active efflux transporter. It 
is widely distributed throughout the body and has a diverse range of substrates. Several vital therapeutic 
agents are substrates to P-gp and their bioavailability is lowered or a resistance is induced because of 
the protein efflux. Hence P-gp inhibitors were explored for overcoming multidrug resistance and poor 
bioavailability problems of the therapeutic P-gp substrates. The sensitivity of drug moieties to P-gp and 
vice versa can be established by various experimental models in silico, in vitro and in vivo. Ever since 
the discovery of P-gp, the research plethora identified several chemical structures as P-gp inhibitors. 
The aim of this review was to emphasize on the discovery and development of newer, inert, non-toxic, 
and more efficient, specifically targeting P-gp inhibitors, like those among the natural herb extracts, 
pharmaceutical excipients and formulations, and other rational drug moieties. The applications of cellular 
and molecular biology knowledge, in silico designed structural databases, molecular modeling studies 
and quantitative structure-activity relationship (QSAR) analyses in the development of novel rational 
P-gp inhibitors have also been mentioned.
Uniterms: P-glycoprotein/inhibitors. Multidrug resistence. Cluster of differentiation 243. Sphingolipids. 
Competitive inhibitors.
Glicoproteína-p (P-gp), uma glicoproteína de transmembrana permeável, é um membro da superfamília 
(ABC) de cassete de gene de ligação de ATP que funciona especificamente como um carreador mediado 
pelo transportador de efluxo ativo primário. É amplamente distribuído por todo o corpo e apresenta 
uma gama diversificada de substratos. Diversos agentes terapêuticos vitais são substratos para P-gp e 
sua biodisponibilidade é reduzida ou a resistência é induzida devido ao efluxo de proteínas. Portanto, 
os inibidores da P-gp foram explorados para a superação da resistência a múltiplas drogas e problemas 
de biodisponibilidade deficiente dos substratos terapêuticos da P-gp. A sensibilidade das moléculas da 
droga à P-gp e vice-versa, pode ser estabelecida por vários modelos experimentais in silico, in vitro e 
in vivo. Desde a descoberta da P-gp, diversas pesquisas identificaram várias estruturas químicas como 
inibidores da P-gp. O objetivo deste presente estudo foi o de enfatizar a descoberta e desenvolvimento 
de inibidores mais novos, inertes, atóxicos e mais eficazes, visando especificamente os da P-gp, como 
aqueles entre os extratos vegetais, excipientes e formulações farmacêuticas, e outras moléculas racionais 
de droga. As aplicações do conhecimento de biologia celular e molecular, bancos de dados estruturais in 
silico, estudos de modelagem molecular e análises da relação quantitativa estrutura-atividade (QSAR) 
no desenvolvimento de novos inibidores racionais da P-gp também foram mencionados.
Unitermos: Glicoproteína-p. Resistência a múltiplas drogas. Cluster de diferenciação 243. Esfingolipídeos. 
Inibidores competitivos.
INTRODUCTION
P-glycoprotein (P-gp), the permeability glycoprotein 
or plasma glycoprotein is an active, efflux, membrane bound 
transport protein pump discovered in 1976 (Juliano, Ling, 
1976). P-gp is a member of ATP binding cassette (ABC) 
super family, multidrug resistance (MDR)/transporter 
associated with antigen processing (TAP), sub-family B, 
and member 1, abbreviated as ABCB1. It is also called 
as MDR1 and PGY1. It has been recently designated as 
CD243 (cluster of differentiation 243). Its efflux mechanism 
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involves the protein binding to the ATP and requires energy 
derived by the hydrolysis of ATP to ADP in the presence 
of adenosine-triphosphatase enzyme (ATPase) (Shekfeh, 
2009). P-gp, which was first identified in cancer cells, is en-
coded by MDR1/ABCB1 gene in humans. The gene shows 
an exclusive over expression in cancer cells. The correlation 
between the up regulation of MDR1 gene mRNA transcrip-
tion and the over expression of the P-gp transport system, 
leading to multidrug resistance (MDR) phenotype, during 
the drug therapy for cancer and several microbial infections 
has been well established. Repetitive treatment with P-gp 
substrates may also enhance the P-gp expression (Krishna, 
Mayer, 2000). A further support to the correlation between 
the P-gp over expression and development of MDR is given 
by the role of P-gp in the metabolism of endogenous sphin-
golipids. The sphingolipids and their metabolites were re-
ported to confer MDR in concert with the efflux transporters 
(Dijkhuis et al., 2003). P-gp was found to be present on the 
surface of biliary canalicular hepatocytes, luminal surface of 
columnar epithelial cells of the lower gastrointestinal tract 
(GIT) including liver, pancreas, small and large intestines, 
jejunum and colon, apical surface of proximal convoluted 
tubular cells of kidney, capillary endothelial cells of blood-
brain barrier (BBB), apical membrane of the placental fetal-
membrane barrier function and in various other tissues like 
lungs, heart, adrenals, prostrate, skin, spleen and skeletal 
muscle (Thiebut et al., 1987). On account of its distribution, 
P-gp can be viewed as a unique defensive barrier network 
against the entry of xenobiotics into the body. This efflux 
carrier decreases the bioavailability of administered drugs 
by preventing their sufficient accumulation intracellularly. 
Ultimately, the efficacy of drugs is lowered. It also alters 
the pharmacokinetics and pharmacodynamics of its sub-
strates by dictating their ADMET (absorption, distribution, 
metabolism, elimination and toxicity) characteristics (Lin, 
2003). The optimal P-gp expression is always appreciated 
for its protective function. But, P-gp over expression leads 
to MDR while its low expression leads to toxic reactions.
This review presents a brief note on the mechanism 
and kinetics of P-gp efflux and discusses about various 
P-gp inhibitors identified under different categories of 
chemical, natural, pharmaceutical and biochemical class-
es. Different possible strategies that can be developed to 
circumvent the protein action were mentioned. Further, the 
interaction between the P-gp substrates/inhibitors/induc-
ers and P-gp has been well differentiated and elucidated.
P-GLYCOPROTEIN SUBSTRATES
P-gp transporter has a diverse array of substrates 
which vary not only in size and structure but also in 
several chemical properties. Since the primary criterion 
subjecting a substrate to P-gp efflux is its interaction with 
the bilayer lipid membrane, a wide range of cationic, li-
pophilic and planar drugs become the protein substrates 
inspite of their structural dissimilarity. This explains the 
vast spread structural specificity or in the practical sense, 
the non-specific nature of P-gp (Higgins, Gottesman, 
1992). However, there is one unifying structural feature 
that is commonly shared among all the substrates of P-gp, 
and that is they all possess spatially separated hydrophilic 
and hydrophobic moieties. The P-gp substrates recon-
stitute most of the clinically efficient agents. Anticancer 
drugs, various pharmacotherapeutic agents that act on 
central nervous system, cardio vascular system and an-
timicrobials are substrates to this efflux protein (Hunter, 
Hirst, 1997; Schinkel, 1999).
MECHANISM AND KINETICS OF P-GLYCO-
PROTEIN EFFLUX
The efflux action of the protein follows a carrier me-
diated primary active transport mechanism. In this process, 
the protein pump export needs direct ATP requirement 
and the energy released from the ATP hydrolysis gives 
the driving force for extrusion process. The efflux takes 
place unidirectionally (out of the cells into the extracellular 
space) and transfers only one molecule at a time. Thus, 
P-gp is a uniporter carrier protein. 
Figure 1 explains the mechanism of action of the 
competitive and non-competitive (non-transported) inhibi-
tors apart from the P-gp efflux kinetics. While a P-gp sub-
strate binds to protein’s transport site and gets translocated 
by the protein, competitive inhibitors compete with the 
substrate drugs for extrusion and occupy all the available 
protein transport sites leaving no space for the P-gp and 
substrate interaction.
Non-competitive inhibitors neither bind to protein’s 
transport site nor are translocated by the protein efflux 
and hence are as well called as non-transported inhibitors. 
They non-competitively inhibit the protein efflux by bind-
ing to an allosteric modulatory site.
Since the number of protein carriers is limited, the 
transport system is capacity limited. The efflux kinetics 
is described by the equation (1), as mixed-order kinetics 
or Michaelis Menten kinetics or saturation or non-linear 
dose dependent kinetics (Jang, Wientjes, Jessie, 2001; 
Varma et al., 2003).
 Jpgp = Vmax. C / Km+C  Equation (1)
Where, 
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Jpgp = P-gp efflux 
Vmax = maximum velocity of P-gp efflux per unit surface 
area
C = substrate concentration
Km = affinity constant or michaelis menten constant (dis-
sociation constant for P-gp mediated efflux). 
At low drug concentrations, where Km >> C,
The efflux follows first order kinetics. The efflux 
rate is proportional to the drug concentration and increases 
linearly with the drug concentration.
At high drug concentrations, where Km << C,
The protein carriers get saturated and the efflux oc-
curs at constant rate. In other words, the efflux rate process 
approaches an asymptote and becomes independent of 
drug concentration. The efflux follows zero order kinetics 
in this case.
In cases where Km = C, the efflux rate is half its 
maximum velocity and assumes mixed order (exhibiting 
zero and first order kinetics together) kinetics.
Characterization of the interaction of certain 
compounds with P-Glycoprotein
It is the nature of interaction of a compound with the 
protein that identifies and establishes it as a P-gp inhibitor 
or substrate or inducer. From the Venn diagram (Figure 
2) describing the interaction of different compounds with 
P-gp as inhibitors/substrates/inducers, it is evident that 
such a classification is not very straight forward. Though 
an effort has been made in this review to provide a vivid 
profile picture of those P-gp interacting compounds dif-
ferentiated in the Venn diagram, the characterization of rest 
other modulators still remains ambiguous. Compounds 
like progesterone, gomisin A, valspodar, elacridar were 
identified as pure inhibitors since they are not P-gp sub-
strates. They neither bind to protein’s transport site nor are 
translocated by the protein efflux. They non-competitively 
inhibit the protein efflux by binding to an allosteric modu-
latory site (Haslam et al., 2008). Cis-flupenthixol, a typi-
cal/classical antipsychotic is another P-gp reverser iden-
tified as a non-transported inhibitor, binding to protein’s 
allosteric binding site (Maki, Hafkemeyer, Dey, 2003). 
However, there are “n” numbers of P-gp inhibitors which 
are its substrates too. They are all competitive inhibitors 
as they compete with the substrate drugs for extrusion 
and thus favour intracellular accumulation of those sub-
strates. Propafenone and its major metabolites 5-hydroxy 
propafenone and N-desalkyl propafenone are all P-gp 
inhibitors but propafenone and N-desalkyl propafenone 
are not P-gp substrates while 5-hydroxy propafenone is 
translocated across the cell membrane by human P-gp. 
Thus, 5-hydroxy propafenone can be distinguished as a 
competitive P-gp inhibitor while the other two compounds 
act non-competitively (Bachmakov et al., 2005). Quini-
dine and amprenavir exhibit an uncertain combination 
of three distinct interactions with P-gp. They act as P-gp 
substrates, inhibitors and also as P-gp inducers suggesting 
an indiscriminate characterization. Artemisinin, on the 
other hand, is a non-transported P-gp inducer. It is a non-
substrate to P-gp and is more or less alike non-competitive 
inhibitor in one point that it exerts its action without being 
FIGURE 1 – P-gp efflux kinetics obtained by plotting a graph 
between substrate concentration (X-axis) and P-gp efflux rate 
(Y-axis). The mechanism of action of the competitive and non-
competitive inhibitors has also been represented.
FIGURE 2 – Venn diagram distinguishing the interaction of 
different compounds with P-gp. The solid circle includes all the 
inhibitors. Dotted circle represents the substrates. The dashed 
circle encloses inducer compounds.
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subject to P-gp efflux. The most conflicting categoriza-
tion is that of piperine and apocyanin. Andrographolide, 
berberin, glycyrrhizin and magniferin are the other natural 
constituents, which are also classified under this category. 
The explanation for their characterization as both induc-
ers and inhibitors is given by their “biphasic protein 
modulation” by which they stimulate the protein efflux at 
lower concentrations and inhibit the same at their higher 
concentrations (Najar et al., 2010). Rifampicin is classi-
fied as an inducing substrate of P-gp as it is transported 
by the protein and as well has an up regulating effect on 
P-gp expression. Digoxin, bromocriptine and cimetidine 
are mere P-gp substrates with neither an inhibitory nor an 
inductive effect on protein function (Vautier et al., 2006).
Classification of P-Glycoprotein inhibitors: the 
past & the present perspective
The candidates which block or bypass the P-gp 
efflux are called as P-gp inhibitors/P-gp modulators/
chemosensitizers/reversal agents. Co-/concurrent adminis-
tration of the P-gp substrate-therapeutics with these P-gp 
inhibitors can prevent/overcome the substrate expulsion 
by P-gp and render the intended therapeutic benefits of the 
substrate drugs. Though several P-gp inhibitors were ear-
lier identified among the available drugs, their toxicity and 
drug interaction profiles drove the researchers to discover 
more rational inhibitors. As of now, the inhibitors were 
identified among various natural products, pharmaceutical 
inert excipients and formulations. Prodrug strategy is also 
being applied to escape P-gp efflux. A few novel antitumor 
drugs, synthetic peptides and P-gp expression suppressors 
are under development to circumvent the protein action. 
The cellular and molecular biologists are now focusing on 
designing inhibitors based on the information extracted 
about the protein’s vital structural organization. Certain 
unique developmental strategies which on implementation 
could hopefully achieve rational prototype molecules have 
also been discussed in this review. Table I enumerates the 
possible rational approaches to strategically develop P-gp 
inhibitors (Balayssaca et al., 2005; Bansal et al., 2009a; 
Yuan et al., 2008; Bansal et al., 2009b).
Small molecule inhibitors (SMIs)
The first, second and third generation inhibitors, 
developed based on screening among the available com-
pounds, parent molecule optimizations and chemical 
syntheses by combinational chemistry approaches, respec-
tively, are together called as SMIs. All these compounds, 
though grouped under the same heading, are structurally 
unrelated and do not share any properties in common, 
except that they are P-gp inhibitors.
First generation inhibitors
This class of inhibitors embodies those pharmaco-
logical agents which were primarily developed for other 
indications but later observed to be P-gp substrates cum 
inhibitors. Verapamil, an antihypertensive calcium channel 
blocker, trifluoperazine, a calmodulin antagonist, cyclo-
sporine, an immunosuppressant, other antihypertensives 
such as quinidine and reserpine, yohimbine, antiestrogenic 
tamoxifen and toremifene, and antineoplastic vincristine, 
all fall under this category. Since most of these compounds 
were P-gp substrates themselves, they interacted with 
the protein, competed with the other substrates and acted 
as competitive inhibitors. Since all the first generation 
inhibitors have been identified this way, they obviously 
were non-selective and less potent. Their P-gp inhibitory 
concentrations reached high toxic levels due to which 
many of these inhibitors failed in clinical trials (Dantzig, 
Alwis, Burgess, 2003).
Second generation inhibitors
The first generation inhibitors were modified struc-
turally viz. their chirality was altered to achieve a better 
or a null innate pharmacological profile so as to largely 
reduce the toxicity of the parent compounds. Dexvera-
pamil, the R-isomer of verapamil without any cardiac 
activity, PSC 833 (valspodar), a cyclosporine A analogue 
lacking immunosuppressive character, MS-209 and sev-
eral other first generation drug derivatives or analogues 
fall under this category. These resultant modulators still 
remained P-gp substrates themselves and showed low 
protein affinity. As such, their P-gp inhibitory dose was 
far beyond the tolerable dose levels. Due to the chiral 
optimization, these second generation chemosensitizers 
ended up as inevitable cytochrome P450 3A4 (CYP450 
3A4) substrates for metabolism, which made them com-
pete with the concurrently administered anticancer P-gp 
substrate drugs whose metabolism was also affected by 
the same system. This caused significant pharmacokinetic 
alterations that unpredictably affected the metabolic and 
clearance mechanisms of the substrate drugs which in turn 
brought about difficulties in adjusting the chemotherapy 
doses in patients. All these problems left this class of in-
hibitors deserted (Thomas, Coley, 2003; Darby, Callaghan, 
McMahon, 2011).
Third generation inhibitors
The quantitative structure-activity relationship 
(QSAR) application to high throughput screening tech-
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TABLE I - Possible approaches to strategically achieve P-gp inhibition
INHIBITION STRATEGY EXAMPLES OF INHIBITOR COMPOUNDS REFERENCES
Small molecule inhibitors (SMIs)
Screening among the available 
compounds (first generation inhibitors)
Balayssaca et al., 2005
Antiarrhythmics: Amiodarone, quinidine, verapamil, felodipine, nifidipine, 
dilitiazem.
Anticancer drugs: Actinomycin D, doxorubicin, vinblastine.
Antibiotics: Clarithromycin, erythromycin.
Antidepressants: Paroxetine, sertraline, desmethylsertraline.
Proton pump inhibitors: Esomeprazole, lansoprazole, omeprazole, pantoprazole.
Others: Cyclosporine A, colchicine, fenofibrate, propafenone, 
reserpine, trifluoperazine, progesterone, ritonavir, 
chlorpromazine, flufenazine, tamoxifen.
Parent molecule optimization (second 
generation inhibitors)
Dexverapamil, gallopamil, PSC 833 (valspodar), MS-209, 
reversin 121, reversin 125.
Bansal et al., 2009b
Chemical synthesis by combinational 
chemistry strategies (third generation 
inhibitors)
XR 9576 (tariquidar), VX-710 (biricodar), GF 120918 
(elacridar), OC 144-093, LY335979 (zosuquidar), mitotane 
(NSC-38721), annamycin.
Bansal et al., 2009b
Others
Natural product screening Herbs, fruits and herbal constituents. Bansal et al., 2009b
Use of pharmaceutical excipients C8/C10 glycerol & polyethylene glycol (PEG) esters, 
sucrose esters, polysorbates, tocopherol esters, polymers, 
amphiphilic diblock copolymers.
Bansal et al., 2009a
Pharmaceutical formulation approaches Bansal et al., 2009a
Polymer formulations: Conventional tablets, micellar systems, hydrogels, microgels, 
nanogels, microparticles, microspheres and nanoparticles.
Lipid formulations: Implantable films, lipid micelle systems, liposomes, 
solid lipid nanoparticles (SLN), lipid nanocapsules 
(LNC), composite solid lipid nanoparticle-microsphere 
systems, emulsifying wax nanoparticles, polymer-lipid 
hybrid nanoparticles (PLN), micro emulsions and self-
microemulsifying drug delivery systems (SMEDDS).
Novel antitumor drugs KP772 (FFC24), 7-benzyl-4-methyl-5-[(2-substituted 
phenyl) ethyl]-7H-pyrrolo [2, 3-d]-pyrimidin-2-amines, 
imitinab and gefitinab.
Yuan et al., 2008
Rational drug design strategy
Prodrug design First generation polyamidoamine (PAMAM) dendrimer 
prodrug derivatives, val-quinidine. 
Yuan et al., 2008
De-novo design To develop competitively inhibiting modulators that can 
target the protein’s SBSs, NBDs and residues involved in 
the protein-pump communication pathways (L339, N508, 
G346, and I306).
Yuan et al., 2008
Synthetic peptides Transmembrane proteins to disrupt the efflux protein TMDs 
assembly.
Yuan et al., 2008
Suppression of P-gp expression Trythanthrin, trifluoperazine, short interfering double 
stranded RNA, elevated levels of reactive oxygen species 
(ROS), oxalyl bis (N-phenyl)hydroxomic acid (OBPHA) and 
copper N-(2-hydroxy acetophenone) glycinate (CuNG) and 
dopamine and cAMP regulated phosphoprotein (DARPP-32).
Yuan et al., 2008
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niques (HTS) and combinational chemistry methods gave 
10-fold more potent compounds when compared to the 
first and second generations. Thus evolved third genera-
tion inhibitors were highly specific, lacked interactions 
with CYP450 3A4 system and required no alterations in 
the chemotherapy doses. XR 9576 (tariquidar, an anthra-
nilamide derivative), a non-transported P-gp inhibitor, 
developed in this pace was stated to inhibit ATPase by 
interacting with a distinct modulatory binding site on the 
protein. It was believed to be the most promising but still 
suspended due to unfavorable toxicity reports in phase 
III trials in lung carcinoma cases. Other compounds 
discovered by this strategy include VX-710 (biricodar, a 
cyclopropyldibenzosuberane modulator, developed by Eli 
Lilly Inc.), GF 120918 (elacridar, an acridonecarboxamide 
derivative, developed by GlaxoSmithKline), OC 144-093, 
mitotane (NSC-38721), annamycin, R101933, ONT-093 
and LY335979 (zosuquidar) (Ozben, 2006).
Upcoming P-glycoprotein inhibitors among the 
natural product extracts
Discoveries in this natural resources area are gaining 
increasing interest since they are safe and non-toxic. The 
grape fruit interactions with several drugs gave the first 
evidence of herbal applications in P-gp inhibition (Bailey 
et al., 1991). Several herbal constituents, as listed in Table 
II (Bansal et al., 2009b; Yuan et al., 2008) were identi-
fied as potent P-gp inhibitors. Though the studies already 
proved most of them effective in vitro, it takes still long 
time to evaluate their suitability for clinical purposes. 
Apart from those tabulated inhibitors, ginsenoside 
Rg3, a red ginseng saponin was reported as a competitive 
P-gp inhibitor (Kim et al., 2003). Antineoplastic lamellarin 
D, a novel pro-apoptotic alkaloid agent of marine origin 
exhibited insensitivity to P-gp mediated drug efflux (Van-
huyse et al., 2005). Gomisin A, a dibenzocyclooctadiene 
TABLE II - List of natural constituents identified as P-gp inhibitors
CATEGORY EXAMPLES REFERENCES
Herbs Garlic, green tea, marine resources. Foster et al., 2001; Jodoin, Demeule, 
Beliveau, 2002
Peptides Kendarimide A, a novel peptide from a 
marine sponge of Haliclona oculata.
Aoki et al., 2004
Fruits Citrus fruit, grape, orange. Ikegawa et al., 2000; Takanaga et al., 1998
Herbal constituents
Glycosides Iridoid and polyethanoid flavonoids, 
picroside II, acteoside. 
Najar et al., 2010 
Curcumin Curcuma longa Anuchapreeda et al., 2002
Ginsenosides Ginseng (Panax ginseng) Bansal et al., 2009b
Piperine Piper nigrum. Bhardwaj et al., 2002
Hyperforin and Hypericin St. John’s wort. Mathijssen et al., 2002
Bitter melon leaf extracts Momordica charantia. Limtrakul, Khantamat, Pintha, 2004
Flavonoids Diosmin from citrus fruit, quercetin from 
tea, ginkgo and St. John’s wort, naringin, 
biochanin, silymarin.
Choi, Jo, Kim, 2004; Choi, Shin, 2005; 
Zhang, Morris, 2003
Terpenoids
Monoterpenoid (R)-(+)-citronellal, (S)-(-)-betacitronellol 
and others from Zanthoxyli fructus extracts.
Yoshida et al., 2006
Sesquiterpenes Extracts from Zinowiewia costaricensis. Munoz-martinez et al., 2005
Diterpenoids Lathyrane from the seeds of caper spurge 
(Euphorbia lathyris).
Jiao et al., 2009
Triterpenoids Derived from the red sea sponge, 
Siphonachalina siphonella.
Jain et al., 2007
Others Root extracts of Stemona curtisii. Limtrakul et al., 2007
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TABLE III - List of pharmaceutical excipients used as P-gp inhibitors and their P-gp inhibitory mechanisms
CATEGORY EXCIPIENT EXAMPLES MECHANISM OF ACTION
Surfactants and solubilizing 
solvents
C8/C10 Glycerol & PEG esters: 
Cremophor, Solutol HS-15, Labrasol, 
Softigen 767, Aconnon E.
Sucrose esters: 
Sucrose monolaurate, sucrose monooleate
Polysorbates: 
Tween 80, Tween 20
Tocopherol esters: 
Tocopheryl-PEG-1000-succinate (TPGS)
The plasma membrane shows the lipid tails 
extending as perturbations. These excipient 
molecules insert themselves between those tails of 
the lipid bilayer and fluidize the membrane. They 
may also interact with the bilayer’s polar heads 
and modify the hydrogen bond or ionic bond forces 
which may add onto their inhibitory action (Lo, 
2003).
Polymers Pluronic block copolymers: 
Poly-(ethylene-oxide) /Poly-(propylene-
oxide) block copolymers (PEO-PPO)
Pluronics inhibit the enzyme ATPase which causes 
ATP depletion. Thus they prevent the sensitization 
and desensitization of protein which are the basic 
requirements for the working of the protein pump 
(Batrakova, Kabanov, 2008).
Lipid excipients Peceol and Gelucire When applied onto CaCo-2 cell culture system, 
these excipients reduced the protein expression 
which can be attributed to their capability of down 
regulating the MDR1 gene expression (Sachs-
barrable et al., 2007).
Thiomers Chitosan-thiobutylamidine (chito-TBA) These are polymers with thiol groups. They interact 
with the cysteine groups located in the P-gp 
transmembrane region and thus inhibit its efflux 
transport function (Werle, Hoffer, 2006).
Others They directly affect the P-gp - substrate binding by 
inhibiting the protein kinase activity. They decrease 
the P-gp phosphorylation and thus modulate P-gp 
mediated efflux (Cornaire et al., 2004).
compound isolated from Schisandra chinensis, showed 
an evidence of altering P-gp substrate interaction non-
competitively and thereby reversing MDR. It is not a P-gp 
substrate by itself and can bind simultaneously to both 
P-gp and substrate. It is also known to inhibit the basal 
P-gp associated ATPase activity (Wan et al., 2006). CBT-
1 is another novel bisbenzylisoquinoline plant alkaloid 
in development as a P-gp inhibitor (Robey et al., 2008). 
The epoxide moiety of laulimalide, a macrolide obtained 
from Hyatella species is a microtubule stabilizing agent 
which has been established as a P-gp inhibitor as well. Its 
antitumor activity was found to be a 100-fold more potent 
than that of taxol in MDR cell lines (Corley et al., 1988).
Pharmaceutical excipients
An ideal P-gp inhibitor is the one that is non-toxic 
with no pharmacological action of its own. Several phar-
maceutical inert additives and functional excipients were 
investigated to study their P-gp inhibitory activity and 
to evaluate their role in enhancing the drug permeability 
across the lipid membrane. P-gp activity is modulated by 
the physical state of lipid bilayer where the protein actu-
ally resides. Several pharmaceutical agents of natural or 
synthetic origin that belong to various categories like the 
cosolvents, surfactants, polymer and lipid excipients were 
identified to have the P-gp inhibitory action (Buggins, 
Dickinson, Taylor, 2007). The mechanism of action differs 
with the type of excipient as presented in Table III (Bansal 
et al., 2009a). Most of these components increase the P-gp 
substrates absorption transport by inhibiting their secretion 
directed transport. They inhibit P-gp efflux by acting on the 
lipid membrane and exhibit fewer side effects. Surfactants 
and polymers solubilize and stabilize the drug molecule. 
They act indirectly and non-specifically by interacting 
with the lipid bilayer. Some surfactants can further de-
crease the P-gp ATPase activity. A few act simultaneously 
by both the mechanisms. Pluronic block copolymers and 
other amphiphilic diblock copolymers modulate P-gp 
activity by inducing the membrane permeability changes 
through reduction in membrane microviscosity and also 
by depletion of cellular ATP levels. Vesicular transport of 
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substrates by micellar structures, modulate P-gp action 
mostly at concentrations greater than the critical micelle 
concentrations (Yuan et al., 2008).
Pharmaceutical formulations
Excipients are safe, not absorbed from the intestine 
or gut and have wide pharmaceutical acceptance with a 
fair history of being incorporated into the parenteral and 
external formulations as solubilizing and stabilizing agents 
(Buggins, Dickinson, Taylor, 2007). Besides, in the present 
scenario, there is increasing development of novel drug 
delivery systems (DDS) like microspheres, nanoparticles 
and liposomes, all of which have inherent P-gp evading 
activity (Kim, Lim, 2002). The stealth particles (stealth 
liposomes) are known to saturate the P-gp carrier, reverse 
the P-gp efflux and thus deliver concentrated drug levels 
across the plasma membrane (Krishna, Mayer, 2000). 
Polymeric conjugates and mixed micelles can bypass the 
P-gp efflux since they are transported into the cells via 
receptor mediated endocytosis in contrast to the typical 
free drug diffusion. The degradation products of poly-
mers or carriers may also block P-gp by direct interaction 
and inhibition (Dabholkar et al., 2006; Kobayashi et al., 
2007). Surfactant polymer nanoparticles were reported to 
overcome P-gp mediated efflux by undergoing endocytic 
vesicular transport (Chavanpatil et al., 2007). As such, a 
combination of both the approaches where P-gp inhibiting 
excipients as well as the novel DDS are applied together, 
may serve as more potent P-gp inhibitors. Systems in 
which the therapeutic agents and sensitizers can be incor-
porated into a single carrier for simultaneous delivery to 
the cells can be explored to further enhance the efficacy 
of chemotherapy (Dharmala, Yoo, Lee, 2008; Wong et 
al., 2004).
Formulation strategies can be:
1. Encapsulating either the chemosensitizer or the drug 
while the other is freely delivered.
2. Co-encapsulation of the both.
Novel antineoplastic drugs
Novel 7-benzyl-4-methyl-5-[(2-substituted phe-
nyl) ethyl] -7H-pyrrolo [2, 3-d] -pyrimidine-2-amine 
series showed remarkable P-gp mediated MDR reversal 
potential by binding to a unique site on tubulin which 
was distinct from other antineoplastic drug binding sites 
(Gangjee et al., 2007). KP772 (FFC24), a new anticancer 
lanthanum compound was reported to block P-gp expres-
sion especially in MDR cancerous cells (Heffeter et al., 
2007). A selective tyrosine kinase (an epidermal growth 
factor receptor) inhibitor, gefitinab used for treating lung 
cancer interacted directly and inhibited P-gp function 
(Kitazaki et al., 2005). In vitro studies showed the selective 
modulation of MDR protein-ATPase activity by several 
4-anilinoquinazoline-derived tyrosine kinase inhibitors 
(TKIs), effective at their submicromolar concentrations. 
Such TKIs include canertinib, EKI- 485, erlotinib, lapa-
tinib, tyrphostin AG1478, and a phenylamino-pyrimidine 
derivative, imatinib. Another phenylamino-pyrimidine 
analogue, nilotinib (AMN107, Tasigna), was designed 
based on the “imatinib-ABL complex” crystal structure. 
Nilotinib proved to be a potent, relatively selective inhibi-
tor of tyrosine kinase activity exhibited by the BCR-ABL 
gene, the platelet-derived growth factor and the mast/stem-
cell growth factor receptor (Tiwari et al., 2009).
Pharmaceutical prodrugs
One of the successful rational attempts would be to 
reduce the substrate-protein affinity by imparting min-
ute changes to the drug’s chemical structure, wherever 
applicable. The limitation with this approach could be 
loss of the drug’s pharmacological action brought about 
by chemical modification. In a drug discovery process, 
prodrugs are often designed to improve the pharmaco-
logical and pharmacokinetic properties of the drugs. 
Val-quinidine, a prodrug obtained by derivatization of 
quinidine was reported successful in circumventing P-gp 
transport (Jain et al., 2004). The first and third generation 
PAMAM dendrimer based prodrugs showed potency as 
membrane permeability enhancing P-gp inhibitors for 
P-gp substrate drugs (Thiagarajan et al., 2010). Pegylated 
substrate-prodrugs and substrate encapsulated liposomal 
pegylation can escape the P-gp efflux (Immordino et al., 
2003). Formulations using PEG-derivatized phospholipids 
altered the pharmacokinetics dramatically by imparting 
long elimination half-lives and small volumes of distribu-
tion (Dadashzadeh, Vali, Rezaie, 2008). Substrates can be 
structurally modified to form conjugates of substrate and 
monoclonal antibody (MAb) for delivery as MAb-prodrug 
system (Guillemard, Saragovi, 2004). Paclitaxel 2’-ethyl 
carbonate, a substrate-prodrug synthesized using radical 
co-polymerization and substrate-copolymer conjugates of 
HPMA are the examples of conjugate DDS which proved 
to be efficient P-gp bypassing systems (Tanino et al., 2007; 
Stastny et al., 1999).
Inhibitors of de-Novo origin
Generation of chemical atomic structures and pre-
diction of the binding ability of such virtually designed 
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ligands and proteins by applying docking programs and 
molecular modeling methods is called de-Novo design. 
Homology modeling based on disulphide cross linking 
established an atomic detailed model for the human ABC 
transporter, P-gp. However, the secondary and tertiary 
structures of P-gp still remain incompletely elucidated due 
to the protein’s crystallization inability for carrying out X-
ray crystallographic analysis. Atomic structural resolution 
models are being generated for P-gp based on the protein 
homology strategy by utilizing the cellular and molecular 
biology knowledge of other ABC transporters like LmrA, 
a bacterial P-gp homologue (from Lactococcus lactis) 
and MsbA, an E. coli derived MDR-ABC transporter 
homologue (Pleban et al., 2005; Eckford, Sharom, 2005; 
Chang, Roth, 2001). The earliest research study suggested 
the presence of two functional substrate binding sites on 
the protein’s transmembrane segments. They were named 
as H and R sites based on their respective selectivity for 
Hoechst 33342 and Rhodamine 123. They are considered 
as the protein’s “active transport sites” since the two sites 
functioned with positive cooperation to bring about P-gp 
efflux transport. Drug binding to any one of these sites 
stimulated the transport by the other. However, the pres-
ence of at least a four more drug binding sites was later 
reported. Distinguishing these newly identified sites as 
transport sites or modulatory sites still remains debatable 
(Haslam et al., 2008; Sharom, Lugo, Eckford, 2005; Mar-
tin et al., 2000). Any inhibitor that can bind to the transport 
site can serve as a competitive inhibitor for P-gp sub-
strates. Polyvalence, the presence of multiple drug binding 
sites within a large and flexible “common protein drug 
pocket”, paves a path to develop a series of inhibitors. Re-
ports stated that homodimers of stipiamide separated with 
spacers of defined-length reversed with greater efficacy, 
the P-gp drug efflux (Sauna et al., 2004). Therefore, P-gp 
efflux blocking can be accomplished either by developing 
inhibitor compounds that can compete with the substrates 
for drug binding active transport sites or by those inhibi-
tors which can bind to distinct modulatory sites affecting 
the allosteric regulation. The latter is categorized as non-
transported inhibitors as they are not substrates for P-gp 
efflux and the former can act as competitive P-gp inhibitors 
(105). The thiomer excipients were reported to covalently 
modify the cysteine residues on TMDs and thereby inhibit 
P-gp. Inhibitor compounds which can specifically bring 
about targeted modification of P-gps NBDs also represent 
a challenging contribution since all the ABC transporters 
possess highly conserved NBDs (Werle, Hoffer, 2006). If 
NBDs are blocked, ATP hydrolysis are affected leading 
to P-gp functional paralysis. Besides, several signaling 
residues have been identified on the TM segments like 
G346, I306, L339 and N508. They are involved in the 
allosteric communication pathways that are set during 
drug occupancy. Any chemosensitizing candidate that can 
cause mutation of these residues can alter the ATP binding 
and hydrolysis steps assuring promising inhibition of the 
protein efflux (Storm et al., 2007).
Peptide inhibitors
Some hydrophobic, linear and cyclic transmembrane 
peptides were designed based on the protein’s primary 
structure of the TMDs, presuming their involvement in 
disrupting the proper assembly of the transporter. There 
were reports that these peptides could effectively resen-
sitize the resistant cancer cells in vitro, to doxorubicin, 
independent of chirality and without demonstrating any 
eminent cell toxicity (Sharom et al., 1998). Research on 
reversin 121 [N (α) -Boc-l-Asp (OBn) -l-Lys (Z) -OtBu], 
a second generation P-gp inhibitor led to the conception of 
fully non-competitive and potent peptidomimetic inhibi-
tors. The replacement of the compound aspartyl residue 
by trans-4-hydroxy-l-Proline (4 (R) Hyp) gave two new 
molecules whose IC50 values were 2- and 7-folds lower 
than that of the parent compound. They were respectively 
named as reversin 11 and reversin 15. The only difference 
between these molecules lies in the presence of a reduced 
carbonyl group of the peptidyl bond in reversin 15. These 
compounds were reported as specifically P-gp targeting 
non-transported inhibitors by binding to an allosteric 
modulatory site other than H and R sites on the protein 
(Arnaud et al., 2010).
P-gp expression suppressers
Since P-gp expression increases by upregulation of 
MDR1 gene RNA levels, compounds like trypthanthrin 
and trifluoperazine, that reverse the MDR1 expression or 
down regulate the MDR1 gene RNA levels are anticipated 
to find scope as novel P-gp inhibitors (Yu et al., 2007; Shin 
et al., 2006). Chemicals such as copper N-(2-hydroxy ace-
tophenone) glycinate (CuNG) and oxalyl bis (N-phenyl)
hydroxomic acid (OBPHA) were reported to resensitize 
the MDR cells to chemotherapy by down regulating the 
P-gp over expression (Majumder et al., 2006). The rever-
sal of P-gp mediated MDR, achieved by a form of gene 
silencer, short hairpin shaped interfering double stranded 
RNA (siRNA) in the post-transcriptional phase exhibited 
selectivity and plasmid/vector targeted delivery limita-
tions (Katoh, Ueno, Takakura, 2008). The expression of 
MDR1 product, P-gp, requires activation of the MDR1 
promoter which is favored by phosphorylated RNA he-
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licase A (RHA). Since the phosphorylation is catalyzed 
by DNA-dependent protein kinase, selection of drugs 
that can inhibit this subunit can be one of the alternative 
approaches to abolish MDR developed by P-gp (Zhong, 
Safa, 2007). Dopamine and cAMP regulated phospho-
protein (DARPP-32) induced downregulation of P-gp 
expression is another hopeful reversal strategy (Hong et 
al., 2008). Elevated intracellular reactive oxygen species 
(ROS) involved in HIF-1α expression regulation and/or 
its stability stands out as one more feasible strategy to 
circumvent P-gp efflux. Multicellular tumor spheroids 
were identified which could induce endogenous oxidative 
stress. Such stress conditions elevate ROS levels which in 
turn stimulate the oxidative defensive systems of the body 
and the defensive systems block the P-gp efflux (Khaitan, 
Dwaraknath, 2009).
Future prospects
Rationalization of the course of evolution and emer-
gence of P-glycoprotein inhibitors
A rational drug design strategy can be used for 
characterizing compounds as P-gp inhibitors/substrates/
inducers as it provides an approach to better understand 
the enigma of P-gp in drug development and delivery. It 
includes the in silico, in vitro screening techniques and 
de-Novo design to study P-gp interaction with different 
compounds so as to establish the protein’s structural basis 
for substrate and modulator recognition. The two stages of 
rational drug design strategy for the evolutionary design 
and evaluation of P-gp inhibitors can be classified as dis-
covery or screening and developmental or characterization 
phases as described in the Figure 3. 
The screening phase involves in silico and in vitro 
studies where the compounds or chemical entities are 
screened for their P-gp affinity. The in silico analysis 
involves the use of chemical libraries and structural da-
tabases for screening. The in vitro tests used to identify 
P-gp interacting compounds include cytotoxicity assays, 
accumulation/efflux assays (based on fluorescent or photo 
affinity studies), transport assays and ATPase assays. 
Thus identified chemical structures can be estab-
lished as P-gp inhibitors/substrates/inducers, based on 
the tests carried out in the characterization phase which 
includes in-situ, mechanistic, in vivo and human studies. 
These studies provide a deeper insight into the affinity 
and specificity of the P-gp inhibitors/substrates/inducers. 
By using this sequential strategy, the compounds can be 
completely characterized starting from their extent of 
sensitivity to P-gp or their P-gp sensitizing efficiency to 
their drug-interaction and toxicity profiles (Bansal et al., 
2009b). This kind of a schematic approach can rational-
ize the discovery and development of newer, inert/safer, 
non-toxic, and more efficient, specifically targeting P-gp 
inhibitors.
FIGURE 3 – Schematic flow chart for the evaluation of a compound’s interaction with P-gp and to distinguish it as an inhibitor/
inducer/substrate. The chart links various study models useful for screening and developing P-gp interacting compounds.
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CONCLUSION
P-gp efflux drastically affects the bioavailability of its 
substrates by decreasing their effective plasma therapeutic 
concentration levels. Co-/concurrent administration of the 
P-gp substrate-therapeutics with the P-gp inhibitors can 
prevent/overcome the substrate expulsion by P-gp and ren-
der the intended therapeutic benefits of the substrate drugs. 
Hence, the research in this area remains an ever-challenging 
mission to the scientists. However, as a concluding remark, 
it should be noted that a caution must be exercised. The drug 
therapy/treatment for diseases using those pharmacological 
agents co-/concurrently administered with P-gp reversal 
agents should be carefully monitored after assessing all the 
possible risks associated with their usage. 
Several efficient P-gp transport blockers were dis-
covered earlier with the aim of enhancing the bioavail-
ability of vital therapeutic P-gp substrates, most of them 
demonstrated shortcomings like unwanted side effects 
and toxicities which impeded their clinical utility. Hence 
there has always been a solid thrust on the pharmaceutical 
industry to develop new chemical entities to avoid or at 
least overcome these restraining phenomena. The recog-
nition of inhibitors among the natural product extracts, 
inert pharmaceutical excipients and formulations to serve 
the cause is gaining utmost importance at present and as 
such, several inhibitor candidates identified under these 
categories have been compiled in this review. The safe, 
non-toxic nature of herbs and the inert, non-gut absor-
bent characters of excipients make them stand out unique 
forever. Though the upcoming researches identify and 
develop uncountable candidates from these classes, only 
the clinical trial reports can establish them as perfect ratio-
nal P-gp inhibitors. A deeper insight into the rational drug 
design becomes indispensable at this stage of research 
to come out with more promising inert and non-toxic 
P-gp inhibitors. Unearthing the promiscuity of the P-gp 
structure, expression and substrate interaction is likely 
to provide a better understanding and open new vistas to 
develop novel inhibitory strategies. The development of 
novel reversal agents requires that the interaction between 
P-gp and the model compounds is well characterized. An 
attempt has been made in the current review to provide a 
P-gp interaction profile of a few compounds. The review 
discussed on several pharmaceutical prodrugs, synthetic 
peptides, certain novel antitumor drugs, de-Novo synthe-
sized inhibitors, and P-gp expression suppressors which 
were reported to successfully escape the P-gp efflux. The 
development of further specific P-gp targeting inhibitors 
is foreseen in the nearest future to tackle and overcome the 
P-gp induced MDR and bioavailability problems.
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